The most common presentation is vaginal bleeding.[1] Other presentations include pelvic mass and uterine polyp. Generally, the clinical findings are non-specific.
Pathology
Uterine adenosarcoma have, by definition, a malignant stroma and benign glandular elements. The World Health Organization (WHO) criteria have a mitotic rate cut point; however, this is often disregarded, as bland-appearing tumours with a low mitotic rate are known to metastasize occasionally.[2]
The prognosis is determined primarily by the cancer stage. Most tumours are discovered at an early stage and have a good prognosis, especially when compared to uterine carcinosarcoma. Five-year survival for stage I and stage III tumours is approximately 80% and 50% respectively.[4]
^Adedipe, TO.; Vine, SJ. (2010). "Mullerian adenosarcoma of the uterus: a rare neoplasm with a need for onco-fertility". Eur J Gynaecol Oncol. 31 (6): 714–6. PMID21319526.
^Arend, R.; Bagaria, M.; Lewin, SN.; Sun, X.; Deutsch, I.; Burke, WM.; Herzog, TJ.; Wright, JD. (Nov 2010). "Long-term outcome and natural history of uterine adenosarcomas". Gynecol Oncol. 119 (2): 305–8. doi:10.1016/j.ygyno.2010.07.001. PMID20688363.